Navigation Links
NextDocs and Novella to Present on eTMF at DIA 2013
Date:6/19/2013

CONSHOHOCKEN, Pa., June 19, 2013 /PRNewswire/ -- NextDocs announced today that it will co-present with Novella, a full service clinical research organization, at DIA 2013, the Drug Information Association annual meeting and conference.  The companies will present case studies that explore best practices for making the transition from paper trial master file to electronic trial master file (eTMF) systems.

Sharon Ames, enterprise program director at NextDocs will present alongside Krystyna Kowalczyk, executive vice president of clinical operations at Novella, in a session entitled, "That Awkward Stage: Transitioning from Paper Trial Master File to eTMF."  The session will examine how to structure a paper-to-electronic transition that incorporates the needs of ongoing studies while also meeting regulatory needs and reducing operational impacts. 

DIA 2013, the 49th annual meeting and conference of the DIA, is the largest multidisciplinary event for the pharmaceutical and life sciences industry, focusing on advancing therapeutic innovation and regulatory science.  The DIA 2013 conference takes place at the Convention and Exhibition Center in Boston from June 23 - 27, 2013. 

NextDocs and Novella's session, "That Awkward Stage: Transitioning from Paper Trial Master File to eTMF," will take place on Monday, June 24, 2013 at 2:30 p.m.  Additionally, NextDocs will be demonstrating its solutions at the DIA conference in booth #1722.

For more information on DIA 2013, visit www.diahome.org.   For more information on NextDocs, visit www.nextdocs.com.

CONTACT:
Dan Cahill
1-917-617-0106
dcahill@roaringpr.com


'/>"/>
SOURCE NextDocs
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. NextDocs Expands Customer Roster by More Than 10 Percent
2. NextDocs Launches QuickStart for Emerging Growth Companies
3. NextDocs 6: The New Enterprise Standard for Regulated Content Management
4. NextDocs Corporation Announces Trial Exchange, a Clinical Portal Designed Specifically for Clinical Trial Sites and Integrated with eTMF
5. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
6. NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinsons Disease
7. Pharma IQ Presents the Latest Trends in Clinical Trial Supply
8. Safinamide Phase III Study Results Presented at 2013 MDS Meeting
9. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
10. Isis Pharmaceuticals to Present a General Corporate Update at its 2013 Annual Meeting of Stockholders and Open House
11. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals plc ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, ... of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ... (Eastern Daylight Time). As previously announced on ... a definitive merger agreement under which Jazz Pharmaceuticals has ...
(Date:6/24/2016)... N.C. , June 24, 2016  Consumers ... decisions and regulators/payers have placed more emphasis on ... environment, patient support programs in the pharmaceutical industry ... patients, medications. Consequently, pharmaceutical companies are focusing on ... they are providing products and services that improve ...
(Date:6/24/2016)...   Bay Area Lyme Foundation , collaborating ... for Tick Borne Illness , Harvard Medical School ... Medicine, University of California, Berkeley, and the Veterans ... finalists of Lyme Innovation , the first ... scientists, clinicians, researchers, entrepreneurs, and investors from several ...
Breaking Medicine Technology:
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... ... , ... People across the U.S. are sharpening their pencils and honing their ... in which patients and their families pay tribute to a genetic counselor by nominating ... of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Grove Investment Group (TGIG), has initiated cultivation and processing operations at its production ... and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of ...
Breaking Medicine News(10 mins):